The obesity management market is expected to expand with a CAGR of 5.2% during the forecast period from 2023 to 2033. The overall market value is projected to grow from US$ 2,095.6 million in 2023 to US$ 3,494.5 million by 2033.
Due to the steep rise in obesity prevalence over the last two decades, the global market is expected to generate significant revenue in the future. The key factors expected to drive the market are:
| Report Attributes or Data Points | Details |
|---|---|
| Global Obesity Management Market Valuation in 2022 | US$ 1,994 million |
| Estimated Global Market Share in 2023 | US$ 2,095.6 million |
| Forecasted Global Market Size by 2033 | US$ 3,494.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 5.2% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Obesity affects one in every three adults in North America. Obesity causes a slew of chronic diseases, many of which can be avoided with proper weight management. Obese patients should be treated for the initial stage of hypertension by losing weight through lifestyle changes, pharmacological treatment, and/or bariatric surgery, according to the AHA.
The NHS in the United Kingdom has suggested that weight loss programs educate people about the dangers of obesity and assist obese people in losing weight. People are becoming more aware of their physical appearance.
The high cost of surgeries and drugs may be a barrier to obesity management. Weight loss surgery is not reimbursed favorably in developing countries. Because weight management is a time-consuming process, medical payers are hesitant to provide reimbursement.
Furthermore, concerns about the safety of obesity management drugs are cruising clinical trials, with only a few drugs reaching the market. Drug-induced cardiovascular disease or cancer can be caused by certain drug formulations. These incidents have the potential to result in drug recalls.
The FDA, for example, has requested that Eisai withdraw its weight-loss drug Belviq from the market after clinical trials revealed an increased incidence of cancer in users.
Principal Consultant
Geriatric population growth in developed countries, primarily due to improved healthcare leading to increased life expectancy, is driving the market. This is because geriatric people are highly susceptible to gaining noticeable body fat while losing muscle mass and functioning ability. As a result, the geriatric population is a critical segment of the market in both the short and long term.
Aside from that, genetics and medication side effects are linked to obesity, which must be handled with the aid of obesity management programs. This helps to fuel the adoption of obesity management services and products.
Liraglutide had a notable market share at 32.4%. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with a long pharmacokinetic profile that preserves biological activity.
These products promote weight loss by suppressing appetite and energy consumption. GLP-1 receptor agonists can also cause significant weight loss in a short period, which might drive growth in the coming decade.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Gastric sleeve surgery will remain dominant in the market during the forecast period, with an estimated 43.5% market share by the end of 2033. Gastric sleeve surgery is very convenient and safe, with excellent patient outcomes.
This procedure induces hormonal changes to aid in weight loss. These hormones not only help with weight loss but also with high blood pressure and heart disease caused by obesity. It is the simplest methodology and requires less time in surgery.
| Category | By Drug Type |
|---|---|
| Top Segment | Liraglutide |
| Market Share in Percentage | 65.2% |
| Category | By Distribution Channel |
|---|---|
| Top Segment | Hospital Pharmacies |
| Market Share in Percentage | 55.8% |
Hospital pharmacies will account for more than 50% of the global distribution channel. Elevated footfall in hospitals for anti-obesity counseling sessions contributes to a large share of market revenue.
The United States is expected to maintain a high growth rate throughout the forecast period with a total market share of more than 63.0% in 2022. Obesity is a major health issue in the country, resulting in a variety of diseases. North America is expected to generate significant revenue in the global market in the coming years. Factors like high population awareness, the presence of prominent drug manufacturers, and the rising prevalence of obesity account for the region's rapid growth in this market. The bupropion and naltrexone segment leads the North American market and is likely to sustain its lead, making it highly appealing to stakeholders.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 35% |
| Europe | 29.5% |
Europe contributes significantly to the overall market's revenue. Obesity in the region is exacerbated by a high intake of processed meats and a high prevalence of lifestyle diseases. The availability of obesity management health programs and government-led obesity management health centers bodes well for the region's obesity management market growth.
Asia Pacific is rapidly emerging as a key market for obesity management. Obesity management programs have emerged as a result of the region's developing countries' excessive rise in obesity incidence as a result of changing lifestyles. This fuels the regional market.
India dominates the South Asian market with a market share of 60.9% and is expected to grow at a CAGR of 4.8%. Rising healthcare expenditures are expected to strengthen the country's market. Obesity among adults is expected to triple between 2010 and 2040, with an estimated 30% of the population being overweight by that time. Obesity is increasing in the country due to increased consumption of energy-dense foods, a sedentary lifestyle, a lack of health care services, and inadequate financial support.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 32.1% |
| Germany | 7% |
| Japan | 4.3% |
Germany held nearly 17.6% of the European market in 2022. The Robert Koch Institute reports that 67% of adults in Germany are overweight. Germany has a significant problem with high cholesterol and type 1 diabetes. The German federal government is enacting policies to combat the country's growing obesity problem. In addition, the number of anti-obesity clinics in the country has increased. These factors will contribute to the expansion of obesity management in the country.
With a market value of US$ 36.6 million in 2022, Russia occupies an important financially rewarding position in Europe. Since 2014, the number of Russians diagnosed with obesity has increased by nearly 50%. According to the WHO, more than 60% of Russians are overweight, with 20% being obese. The Russian Health Ministry is constantly striving to create strategies for enhancing the population's overall health. According to the World Factbook, the prevalence of adult obesity in Russia is 23.1%.
The regional market in China is expanding at a CAGR of 4.3% and is expected to account for more than 42% of the East Asian market over the forecast period. According to national survey data, more than half of all Chinese adults are now overweight or obese. Rapid economic growth in the country in recent decades has resulted in significant changes in lifestyle, diet, and exercise habits. According to the National Health Commission report from 2020, more than half of adults are classified as overweight, with 16.4% being obese.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 5.1% |
| China | 6.6% |
| India | 6.4% |
| Australia | 4.4% |
Business models evolve sometimes as a result of changes in the obesity management industry, and sometimes as a result of technological advancements, resulting in the emergence of new and exciting market trends.
Standout Market Players You Should Know: Allurion Insights, Apollo Endosurgery, Inc., Obalon Therapeutics, and Glyscend Therapeutics
Launch:
Allurion Insights, a new and powerful addition to the Allurion Virtual Care Suite, was launched today by Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences. Allurion Insights is a weight-loss provider-specific integrated remote patient monitoring and telehealth solution.
Approval:
Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, announced that the US Food and Drug Administration (FDA) has approved the ORBERATM Intragastric Balloon to help adult patients with obesity (BMI 30 to 40) lose and maintain weight.
Approval:
Obalon Therapeutics is making its stock market debut with a $75 million IPO to fund the commercialization of its weight loss balloon device in the United States. The product launch comes just a few weeks after Obalon filed for an IPO and revealed that its ingestible weight loss balloon had received FDA PMA approval.
Financing Round:
Glyscend Therapeutics has completed a $20.5 million Series A financing round. The round of funding was led by healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures, and will be used to support the development of the company's novel oral polymer therapy for patients with T2D and other metabolic diseases. In 2019, Breakout Labs provided seed funding.
The overall market is relatively consolidated, with only a few leading players competing. Humongous players in this market are involved in Research and Development for product innovation and the development of existing products. GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. are among the prominent companies operating in the global market.
| Date | January 2018 |
|---|---|
| Company Name | H2-Pharma |
| Strategy | Collaboration |
| Details | H2-Pharma announced a collaboration with Cheplapharm Arzneimittel GmbH in January 2018 and re-launched XENICAL® 120 mg capsules through its newly formed branded division. |
| Date | February 2020 |
|---|---|
| Company Name | VIVUS, Inc. |
| Strategy | Collaboration |
| Details | VIVUS, Inc. announced in February 2020 that its Korean marketing partner, Alvogen, had launched Qsymia in the Republic of Korea. |
| Date | June 2021 |
|---|---|
| Company Name | Novo Nordisk |
| Strategy | FDA approval |
| Details | Novo Nordisk received FDA approval for Wegovy semaglutide injection in adults with at least one weight-related condition in June 2021. |
The market is expected to develop a CAGR of 5.2% through 2033.
The market recorded a 4% CAGR from 2018 to 2022.
The market is estimated to secure a valuation of US$ 2,095.6 million in 2023.
North America is leading the market, with a share of 35%.
The United States, Japan, and Germany dominate the global market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Bupropion and Naltrexone 5.3.2. Orlistat 5.3.3. Lorcaserin 5.3.4. Phentermine and Topiramate 5.3.5. Liraglutide 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Surgery Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Surgery Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Surgery Type, 2023 to 2033 6.3.1. Gastric Bypass Surgery 6.3.2. Adjustable Gastric Banding Surgery 6.3.3. Gastric Sleeve Surgery 6.3.4. Duodenal Switch Surgery 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Surgery Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Surgery Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospitals Pharmacies 7.3.2. Retail Pharmacies 7.3.3. E-commerce 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Surgery Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Surgery Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Surgery Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Surgery Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug Type 11.2.3. By Surgery Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Surgery Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug Type 12.2.3. By Surgery Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Surgery Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug Type 13.2.3. By Surgery Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Surgery Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Type 14.2.3. By Surgery Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Surgery Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Surgery Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Surgery Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Surgery Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Surgery Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Surgery Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Surgery Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Surgery Type 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Surgery Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Surgery Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Surgery Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Surgery Type 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Surgery Type 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Surgery Type 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Surgery Type 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Surgery Type 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Surgery Type 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Surgery Type 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Surgery Type 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Surgery Type 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Surgery Type 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Surgery Type 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Surgery Type 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Surgery Type 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Drug Type 16.22.2.2. By Surgery Type 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Drug Type 16.23.2.2. By Surgery Type 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Surgery Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. GlaxoSmithKline Plc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. VIVUS, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Novo Nordisk A/S 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Currax Pharmaceuticals LLC 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Cheplapharm Arzneimittel GmbH 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Bausch Health Companies Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Takeda Pharmaceuticals, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Pfizer Inc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. F. Hoffmann-La Roche Ltd 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. AstraZeneca 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Herbalife Ltd. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Obesity Management Market
